Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Relacorilant in combinatie met Nab-Paclitaxel bij geavanceerde, platina-resistente, hoogwaardige epitheliale ovarium-, primaire peritoneale of eileiderkanker

24 september 2026 bijgewerkt door: Corcept Therapeutics

Een fase 3-studie van Relacorilant in combinatie met Nab-Paclitaxel versus Nab-Paclitaxel monotherapie bij geavanceerde, platina-resistente, hoogwaardige epitheliale ovarium-, primaire peritoneale of eileiderkanker (ROSELLA)

The primary objectives of this study are to evaluate progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS) (evaluated independently, as dual primary endpoints) in patients treated with intermittent regimen of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel monotherapy.

Studie Overzicht

Gedetailleerde beschrijving

As there are no currently approved therapies or effective standard of care for heavily pretreated patients with ovarian cancer who have exhausted single-agent chemotherapy and/or bevacizumab, the combination of intermittently administered relacorilant and nab-paclitaxel may demonstrate a substantial improvement without increased toxicity compared with nab-paclitaxel.

Patients will receive study treatment until confirmed progressive disease (PD) or unacceptable toxicity. All patients will be followed for the collection of study endpoints, inclusive of disease progression and survival.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

381

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Buenos Aires
      • CABA, Buenos Aires, Argentinië, C1280AEB
        • Site 393
      • Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentinië, C1426ANZ
        • Site 381
    • Córdoba Province
      • Córdoba, Córdoba Province, Argentinië, X5004FHP
        • Site 415
      • Córdoba, Córdoba Province, Argentinië, X5008 HHW
        • Site 401
      • Córdoba, Córdoba Province, Argentinië, X5016
        • Site 395
    • Mendoza Province
      • Mendoza, Mendoza Province, Argentinië, M5500AYB
        • Site 404
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentinië, 2000
        • Site 391
      • Rosario, Santa Fe Province, Argentinië, S2000KDS
        • Site 412
    • New South Wales
      • St Leonards, New South Wales, Australië, 2065
        • Site 426
    • Queensland
      • Benowa, Queensland, Australië, 4217
        • Site 417
    • Victoria
      • Melbourne, Victoria, Australië, 3000
        • Site 414
      • Melbourne, Victoria, Australië, 3128
        • Site 419
      • Aalst, België, 9300
        • Site 328
      • Brussels, België, B- 1200
        • Site 109
      • Charleroi, België, 6000
        • Site 326
      • Hasselt, België, 3500
        • Site 325
      • Leuven, België, 3000
        • Site 108
      • Liège, België, B-4000
        • Site 327
      • Porto Alegre, Brazilië, 90035-001
        • Site 421
    • Brasília - DF
      • Brasília, Brasília - DF, Brazilië, 70297-400
        • Site 424
    • Ceará
      • Fortaleza, Ceará, Brazilië, 60170-170
        • Site 382
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brazilië, 41950-640
        • Site 384
    • Minas Gerais
      • Belo Horizonte, Minas Gerais, Brazilië, 30210-040
        • Site 383
    • Rio Grande do Norte
      • Natal, Rio Grande do Norte, Brazilië, 59062-000
        • Site 390
    • Rio de Janeiro
      • Rio de Janeiro, Rio de Janeiro, Brazilië, 22250-905
        • Site 380
    • São Paulo
      • São Paulo, São Paulo, Brazilië, 01321001
        • Site 376
      • São Paulo, São Paulo, Brazilië, 01327-001
        • Site 389
      • São Paulo, São Paulo, Brazilië, 01409-002
        • Site 413
      • São Paulo, São Paulo, Brazilië, 01509-900
        • Site 374
      • São Paulo, São Paulo, Brazilië, 01509010
        • Site 001
    • Ontario
      • Toronto, Ontario, Canada, M4N 3M5
        • Site 117
    • Quebec
      • Montreal, Quebec, Canada, H4A 3J1
        • Site 273
      • Lille, Frankrijk, 59020
        • Site 306
      • Montpellier, Frankrijk, 34298
        • Site 347
      • Nancy, Frankrijk, 54100
        • Site 307
      • Nice, Frankrijk, 06189
        • Site 310
      • Paris, Frankrijk, 75015
        • Site 289
      • Plérin, Frankrijk, 22190
        • Site 323
      • Budapest, Hongarije, 1122
        • Site 322
      • Debrecen, Hongarije, 4032
        • Site 290
      • Győr, Hongarije, 9024
        • Site 348
      • Haifa, Israël, 3436212
        • Site 309
      • Jerusalem, Israël, 911201
        • Site 080
      • Tel Aviv, Israël, 6423906
        • Site 203
      • Catania, Italië, 95126
        • Site 321
      • Legnago, Italië, 37045
        • Site 320
      • Milan, Italië, 20141
        • Site 122
      • Pavia, Italië, 27100
        • Site 295
      • Roma, Italië, 161
        • Site 161
      • Rome, Italië, 00168
        • Site 124
      • Torino, Italië, 10128
        • Site 293
      • Treviso, Italië, 31100
        • Site 319
      • Gdynia, Polen, 81-519
        • Site 341
      • Poznan, Polen, 61-886
        • Site 331
      • Siedlce, Polen, 08-110
        • Site 329
      • Badalona, Spanje, 08916
        • Site 349
      • San Sebastián, Spanje, 20014
        • Site 311
      • Valencia, Spanje, 46026
        • Site 330
      • Cheltenham, Verenigd Koninkrijk, GL53 7AN
        • Site 366
      • London, Verenigd Koninkrijk, NW1 2PG
        • Site 055
      • Manchester, Verenigd Koninkrijk, M20 4BX
        • Site 344
      • Northwood, Verenigd Koninkrijk, HA6 2RN
        • Site 345
    • East Sussex
      • Brighton, East Sussex, Verenigd Koninkrijk, BN2 1ES
        • Site 367
    • Somerset
      • Taunton, Somerset, Verenigd Koninkrijk, TA1 5DA
        • Site 351
    • Arizona
      • Phoenix, Arizona, Verenigde Staten, 85016
        • Site 318
      • Tucson, Arizona, Verenigde Staten, 85719
        • Site 277
    • California
      • Irvine, California, Verenigde Staten, 92618
        • Site 350
      • La Jolla, California, Verenigde Staten, 92093
        • Site 364
      • Palo Alto, California, Verenigde Staten, 94304
        • Site 150
      • San Francisco, California, Verenigde Staten, 94109
        • Site 278
      • San Francisco, California, Verenigde Staten, 94143
        • Site 014
      • Solvang, California, Verenigde Staten, 93463
        • Site 316
    • Colorado
      • Aurora, Colorado, Verenigde Staten, 80045
        • Site 032
    • Florida
      • Miami Beach, Florida, Verenigde Staten, 33140
        • Site 335
      • Weston, Florida, Verenigde Staten, 33331
        • Site 042
    • Georgia
      • Atlanta, Georgia, Verenigde Staten, 30322
        • Site 009
      • Atlanta, Georgia, Verenigde Staten, 30342
        • Site 272
      • Gainesville, Georgia, Verenigde Staten, 30548
        • Site 372
      • Savannah, Georgia, Verenigde Staten, 31405
        • Site 291
    • Illinois
      • Evanston, Illinois, Verenigde Staten, 60201
        • Site 315
      • Hinsdale, Illinois, Verenigde Staten, 60521
        • Site 314
      • Urbana, Illinois, Verenigde Staten, 61801
        • Site 346
    • Indiana
      • Indianapolis, Indiana, Verenigde Staten, 46260
        • Site 339
    • Kansas
      • Overland Park, Kansas, Verenigde Staten, 66211
        • Site 200
      • Overland Park, Kansas, Verenigde Staten, 66211
        • Site 334
    • Kentucky
      • Louisville, Kentucky, Verenigde Staten, 40241
        • Site 279
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02114
        • Site 128
    • New Jersey
      • New Brunswick, New Jersey, Verenigde Staten, 08901
        • Site 288
    • New Mexico
      • Albuquerque, New Mexico, Verenigde Staten, 87131
        • Site 292
    • New York
      • Flushing, New York, Verenigde Staten, 11355
        • Site 275
    • Ohio
      • Cincinnati, Ohio, Verenigde Staten, 45242
        • Site 298
      • Cincinnati, Ohio, Verenigde Staten, 45459
        • Site 304
    • Oregon
      • Portland, Oregon, Verenigde Staten, 97210
        • Site 280
      • Portland, Oregon, Verenigde Staten, 97213
        • Site 317
      • Portland, Oregon, Verenigde Staten, 97239
        • Site 049
    • Pennsylvania
      • Bethlehem, Pennsylvania, Verenigde Staten, 18015
        • Site 337
      • Pittsburgh, Pennsylvania, Verenigde Staten, 15213
        • Site 127
    • South Dakota
      • Rapid City, South Dakota, Verenigde Staten, 57701
        • Site 276
    • Tennessee
      • Germantown, Tennessee, Verenigde Staten, 38138
        • Site 368
      • Nashville, Tennessee, Verenigde Staten, 37203
        • Site 281
    • Texas
      • Austin, Texas, Verenigde Staten, 78731
        • Site 229
      • Bedford, Texas, Verenigde Staten, 76022
        • Site 312
      • Fort Worth, Texas, Verenigde Staten, 76104
        • Site 297
      • San Antonio, Texas, Verenigde Staten, 78240
        • Site 392
      • The Woodlands, Texas, Verenigde Staten, 77380
        • Site 301
    • Virginia
      • Norfolk, Virginia, Verenigde Staten, 23502
        • Site 300
      • Richmond, Virginia, Verenigde Staten, 23298
        • Site 365
    • Wisconsin
      • Milwaukee, Wisconsin, Verenigde Staten, 53226
        • Site 121
      • Gyeonggi-do, Zuid -Korea, 10408
        • Site 397
      • Seoul, Zuid -Korea, 03080
        • Site 399
      • Seoul, Zuid -Korea, 03722
        • Site 398
      • Seoul, Zuid -Korea, 05505
        • Site 403
      • Seoul, Zuid -Korea, 06273
        • Site 400
      • Seoul, Zuid -Korea, 06351
        • Site 396
      • Seoul, Zuid -Korea, 08308
        • Site 402
      • Seoul, Zuid -Korea, 42601
        • Site 409

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Vrouw

Beschrijving

Inclusion Criteria:

  • Signed and dated Institutional Review Board/Independent Ethics Committee-approved informed consent form prior to study-specific screening procedures.
  • Confirmed histologic diagnosis of high-grade (Grade 3) serous, epithelial ovarian, primary peritoneal, or fallopian tube carcinoma.
  • Patients must have platinum-resistant disease (defined as RECIST v1.1 defined progression <6 months from completion of a platinum-containing therapy).
  • Must consent to provide archival tumor-tissue block or slides. Patients may consent to an optional tumor biopsy if archival tumor is unavailable.
  • Has a life expectancy of ≥3 months.
  • At least one lesion that meets the definition of measurable disease by RECIST v1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
  • Able to comply with protocol requirements.
  • Able to swallow and retain oral medication and does not have uncontrolled emesis.
  • Received at least 1 but ≤3 lines of prior systemic anticancer therapy and at least 1 prior line of platinum therapy and prior treatment with bevacizumab is required.
  • Has adequate organ function meeting the following laboratory-test criteria: Absolute neutrophil count (ANC) ≥1500 cells/mm^3, Platelet count ≥100,000/mm^3, Hemoglobin ≥9 g/dL, Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤2.5 × upper limit of normal (ULN), or ≤5 × ULN in context of liver metastases, Total bilirubin ≤1.5 × ULN, and Albumin ≥3 g/dL, and creatinine clearance >40 mL/min/1.73 m^2 (measured or estimated).
  • Negative pregnancy test for patients of childbearing potential; patients of childbearing potential must agree to use highly effective contraceptive method(s); hormonal contraceptives are not allowed.
  • Coronavirus disease (COVID-19) approved vaccines are accepted concomitant medications when recommended by the Investigator.

Exclusion Criteria:

  • Has clinically relevant toxicity from prior systemic anticancer therapies or radiotherapy that has not resolved to ≤Grade 1 prior to randomization.
  • Has had any major surgery within 4 weeks prior to randomization.
  • Has low-grade endometrioid, clear cell, mucinous, or sarcomatous histology, or mixed tumors containing any of these histologies, or low-grade or borderline ovarian tumor.
  • Has primary platinum-refractory disease, defined as disease that did not respond to or has progressed ≤1 month of the last dose of first-line platinum-containing chemotherapy.
  • Has not received prior bevacizumab treatment.
  • Has been treated with the following prior to randomization: chemotherapy, immunotherapy, investigational agent treatments for disease under study within 28 days before first dose of study drug, radiotherapy not completed at least 2 weeks prior to first dose of study drug, hormonal anticancer therapies within 7 days of first dose of study drug, and systemic, inhaled, or prescription strength topical corticosteroids within 21 days of first dose of study drug.
  • Has received wide-field radiation to more than 25% of marrow-bearing areas.
  • Has toxicities of prior therapies that have not resolved by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0, ≤Grade 1.
  • Requires treatment with chronic or frequently used oral corticosteroids for medical conditions or illnesses.
  • Has a history of severe hypersensitivity or severe reaction to any of the study drugs.
  • Is receiving concurrent treatment with mifepristone or other glucocorticoid receptor (GR) modulators.
  • Has peripheral neuropathy from any cause >Grade 1.
  • Pregnant or lactating patients or patients expecting to conceive children within the projected duration of the trial, starting with the screening visit through at least 1 month after the last dose of relacorilant, or 6 months after the last dose of nab-paclitaxel whichever is the longest.
  • Has clinically significant uncontrolled condition(s) or condition which, in the opinion of the Investigator, may confound the results of the trial or interfere with the patient's safety or participation.
  • Has current chronic/active infection with human immunodeficiency virus or current chronic/active infection with hepatitis C virus or hepatitis B virus.
  • Has any untreated or symptomatic central nervous system (CNS) metastases.
  • Patients with a history of other malignancy within 3 years prior to randomization.
  • Is taking a concomitant medication that is a strong cytochrome P450 (CYP)3A inhibitor or strong CYP3A inducer, or that is a substrate of CYP3A with a narrow therapeutic window.
  • Concurrent treatment on other investigational treatment studies for the treatment of ovarian, fallopian tube, or primary peritoneal cancer.
  • Has received a live vaccine within 30 days prior to the study start date.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Relacorilant 150 mg With Nab-paclitaxel 80 mg/m^2

Patients receive nab-paclitaxel 80 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle in combination with intermittent relacorilant (150 mg relacorilant once daily on the day before, the day of, and the day after nab-paclitaxel), administered orally under fed conditions. Relacorilant will not be administered on Cycle 1 Day -1.

Relacorilant is administered as capsules for oral dosing once daily on the day before, the day of, and the day after nab-paclitaxel administration.

Andere namen:
  • Lifyorli

Nab-paclitaxel is administered as intravenous (IV) infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle.

Actieve vergelijker: Nab-paclitaxel 100 mg/m^2

Patients receive nab-paclitaxel 100 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle.

Nab-paclitaxel is administered as IV infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)
Tijdsspanne: Up to 20 months

PFS was assessed as the time from randomization until the time of first documented progressive disease (PD) or death due to any cause, whichever occurs first. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or an unequivocal progression in a non-target lesion, or the appearance of new lesions.

Up to 20 months
Overall Survival
Tijdsspanne: Up to 32 months

Overall survival (OS) was assessed as the time from randomization to death by any cause. The data values are Kaplan-Meier estimates.

Up to 32 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
PFS as Assessed by the Investigator
Tijdsspanne: Up to 20 months

PFS was assessed as the time from randomization until the time of first documented progressive disease (PD) by RECIST v1.1, or death due to any cause, whichever occurs first.

Up to 20 months
Objective Response as Assessed by the Investigator
Tijdsspanne: Up to 20 months

Objective response was assessed as the proportion of patients with measurable disease at baseline who attained complete response (CR) or partial response (PR). Confirmation of the response was not required for this outcome measure per RECIST v1.1 criteria for randomized controlled clinical trials. Responses were assessed by imaging, using RECIST v1.1 criteria for target lesions: CR, Disappearance of all target lesions; PR, ≥30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Up to 20 months
Best Overall Response as Assessed by the Investigator
Tijdsspanne: Up to 20 months

Best overall response was assessed as the proportion of patients with at least 1 post Baseline scan who attained CR, PR, stable disease (SD), or PD as best response by RECIST v1.1.

Up to 20 months
Duration of Confirmed Responses as Assessed by the Investigator
Tijdsspanne: From the time of confirmed CR or PR to the time of the first PD or death (Up to 18 months)

The median duration of response is presented for confirmed responses (CR or PR) per RECIST v1.1. Duration of response was from the first documented and confirmed response to the first objectively documented PD as assessed by the Investigator, or death due to any cause, whichever occurs first.

From the time of confirmed CR or PR to the time of the first PD or death (Up to 18 months)
Clinical Benefit Rate at 24 Weeks as Assessed by BICR and the Investigator
Tijdsspanne: 24 weeks

Clinical benefit rate was assessed as the proportion of patients who attained CR, PR, or stable disease (SD) for 24 weeks per RECIST v1.1 as assessed by BICR and as assessed by the Investigator.

24 weeks
Cancer Antigen (CA)-125 Response
Tijdsspanne: Up to 24 months

CA-125 response was assessed per Gynecologic Cancer Intergroup (GCIG) criteria defined as ≥50% reduction in CA-125 from a pretreatment sample and maintained for ≥28 days in patients with a pretreatment sample that is at least twice the upper limit of the reference range within 2 weeks before starting the treatment. In addition, patients who have a CA-125 response and whose CA-125 level fell to within the reference range were classified as CA-125 complete responders.

Up to 24 months
Combined Overall Response Rate by RECIST v1.1 and CA-125 Defined by GCIG Criteria
Tijdsspanne: Up to 15 months

Combined response was assessed as the proportion of patients with tumor response per RECIST v1.1 assessed by the investigator and for CA-125 response per GCIG criteria.

Up to 15 months
Number of Patients With One or More Adverse Events
Tijdsspanne: Up to 22 months
Up to 22 months
Number of Patients Who Discontinued the Study Treatment Due to an Adverse Event
Tijdsspanne: Up to 25 months
Up to 25 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie directeur: Adrian Jubb, MBChB, PhD, FRCPath, Corcept Therapeutics

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

29 juni 2022

Primaire voltooiing (Werkelijk)

31 maart 2025

Studie voltooiing (Geschat)

1 december 2026

Studieregistratiedata

Eerst ingediend

4 februari 2022

Eerst ingediend dat voldeed aan de QC-criteria

16 februari 2022

Eerst geplaatst (Werkelijk)

25 februari 2022

Updates van studierecords

Laatste update geplaatst (Werkelijk)

25 september 2026

Laatste update ingediend die voldeed aan QC-criteria

24 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • CORT125134-556
  • GOG-3073 (Andere identificatie: Gynecologic Oncology Group)
  • ROSELLA Study 556 (Andere identificatie: Corcept Therapeutics)
  • ENGOT-OV72 (Andere identificatie: European Network of Gynaecological Oncological Trial Groups)
  • APGOT-Ov10 (Andere identificatie: Asia-Pacific Gynecologic Oncology Trials Group)
  • LACOG 0223 (Andere identificatie: Latin American Cooperative Oncology Group)
  • ANZGOG2221/2023 (Andere identificatie: Australia New Zealand Gynaecological Oncology Group)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren